U.S. Communications Stock News

Fresh coverage of Harrow (HROW) is drawing attention to its move from an ophthalmic compounder to an integrated eye care pharma platform, built around acquired FDA-approved drugs and long-run revenue and margin targets. See our latest analysis for Harrow. At a share price of $47.90, Harrow has recently had a softer 1 day share price return of a 1.22% decline. However, its 90 day share price return of 17.34% and 1 year total shareholder return of 41.51% indicate that momentum has been building...

Archrock Inc recently reported a very large year-over-year EPS increase alongside higher profit margins and stronger free cash flow per share, reflecting improving fundamentals and operational efficiency. What stands out is that this combination of earnings strength and rising cash generation has emerged alongside positive technical momentum, suggesting growing investor attention to the company’s profitability profile. With this backdrop of sharply improving earnings, we’ll now explore how...

The Goldman Sachs Group, Inc.'s ( NYSE:GS ) dividend will be increasing from last year's payment of the same period to...

Key Insights Given the large stake in the stock by institutions, Zhihu's stock price might be vulnerable to their...

Key Insights Aptera Motors' significant insider ownership suggests inherent interests in company's expansion A total of...

GoodRx Holdings (NASDAQ:GDRX) has had a rough three months with its share price down 31%. However, the company's...

The board of Carriage Services, Inc. ( NYSE:CSV ) has announced that it will pay a dividend on the 2nd of March, with...

Key Insights Significantly high institutional ownership implies Cytek Biosciences' stock price is sensitive to their...

With a median price-to-sales (or "P/S") ratio of close to 1.3x in the Commercial Services industry in the United...

The board of KeyCorp ( NYSE:KEY ) has announced that it will pay a dividend on the 13th of March, with investors...

We feel now is a pretty good time to analyse Sangamo Therapeutics, Inc.'s ( NASDAQ:SGMO ) business as it appears the...

The board of AGCO Corporation ( NYSE:AGCO ) has announced that it will pay a dividend on the 16th of March, with...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Northwest Natural Holding Company's ( NYSE:NWN ) investors are due to receive a payment of $0.4925 per share on 13th of...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

Stagwell (STGW) has drawn fresh attention after announcing that SPORT BEACH will become a dedicated business unit focused on connecting athletes, brands, and creatives in sports marketing, with global expansion and high profile partners. See our latest analysis for Stagwell. The SPORT BEACH announcement comes as Stagwell’s share price return has been strong in the short term, with a 7 day share price return of 17.99% and a year to date share price return of 38.69%. By contrast, the 1 year...

Emerson Electric recently delivered a total return of more than 21% since initial analyst coverage, raised its dividend by over 5% late last year, and is scheduled to report its first-quarter results and host an investor call on February 3, 2026. The unusually strong dividend increase, combined with investor focus on the upcoming earnings update, is sharpening attention on the company’s turnaround progress and capital return approach. Next, we’ll examine how this larger dividend increase may...

Autohome (ATHM) is back in focus after JPMorgan Chase & Co. cut its rating from overweight to neutral and reduced its outlook, just as the company announced a special dividend for shareholders. See our latest analysis for Autohome. At a share price of $23.09, Autohome’s recent moves, including crossing below its 200 day moving average and the JPMorgan downgrade, sit against a year to date share price return of 1.81% and a 1 year total shareholder return decline of 10.20%. This suggests near...

In early January 2026, Radware reported discovering ZombieAgent, a new zero-click indirect prompt injection vulnerability targeting OpenAI’s Deep Research agent, which could enable invisible data theft, persistent agent hijacking, and security control bypasses for enterprise users. By exposing a previously unseen attack path against AI agents, Radware is positioning itself at the forefront of securing emerging generative AI deployments for enterprises. Next, we’ll examine how Radware’s...

Gentex (GNTX) has attracted fresh attention after announcing the Ops-Core NOMAD System, a low-profile head harness designed to mount night vision and visual augmentation gear without traditional helmets for specialized military and law-enforcement users. See our latest analysis for Gentex. Despite the Ops-Core NOMAD launch highlighting Gentex’s defense and specialty gear capabilities, recent share price momentum has been muted, with a 30 day share price return of 1.53% and a 1 year total...

In early January 2026, Texas Instruments introduced new automotive semiconductors aimed at enhancing vehicle safety and supporting up to Level 3 autonomy, while also collaborating with Hubble Network and Afero to integrate global, low-power connectivity into its Bluetooth Low Energy and Wi‑Fi microcontrollers for large‑scale IoT deployments. These moves extend TI’s reach across automotive and IoT ecosystems by embedding connectivity, security, and edge AI directly into its chips, potentially...

In recent days, ESAB reported third-quarter earnings and revenue ahead of analyst expectations, raised its full-year guidance, and appointed AI expert Dr. Sébastien Martin to its Board of Directors to support the company’s artificial intelligence agenda. These developments underscore how ESAB is pairing stronger operational performance with an intensified AI focus at the board level, potentially influencing how it allocates capital and prioritizes growth initiatives. We’ll now explore how...

Liquidia Corporation recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, highlighting updates on its pulmonary hypertension franchise, including lead drug Yutrepia. Investor commentary points to Yutrepia’s early commercial traction and milestone progress, helped by its delivery and tolerability advantages over existing therapies, as a key driver of renewed attention on Liquidia. We’ll now examine how Yutrepia’s early sales momentum and clinical...